Anavekar Nandan S, Anavekar Nagesh S
Clinical Pharmacology & Therapeutics, University of Melbourne, Austin Health, Studley Road, Heidelberg 3084, Australia.
Curr Heart Fail Rep. 2005 Dec;2(4):165-73. doi: 10.1007/BF02696646.
Heart failure (HF) is a clinical syndrome that occurs when the ability of the heart to meet the requirements of the body fails. Myocardial infarction (MI) is a common antecedent event that predisposes a patient to HF. Loss of cardiac function following MI occurs in the context of myocyte death and ventricular remodeling. The clinical significance of HF following MI is underscored by the fact that among MI survivors, the risk of death is markedly elevated in those who develop HF compared with those who do not. Various modifying factors associated with the development of HF following MI have been identified. Use of multimodality therapy with improved clinical outcomes for HF has increased the need to specifically identify the failing heart at an earlier stage. The ability to identify heart failure early in its pathogenesis will enable finer risk stratification following MI. This article reviews various risk predictors for the development of HF following MI.
心力衰竭(HF)是一种临床综合征,当心脏满足身体需求的能力衰竭时就会发生。心肌梗死(MI)是使患者易患HF的常见前期事件。MI后心脏功能丧失发生在心肌细胞死亡和心室重塑的背景下。MI后发生HF的临床意义体现在以下事实上:在MI幸存者中,发生HF的患者与未发生HF的患者相比,死亡风险显著升高。已经确定了与MI后HF发生相关的各种调节因素。使用多模式治疗改善HF的临床结局增加了在更早阶段特异性识别衰竭心脏的需求。在其发病机制早期识别心力衰竭的能力将使MI后的风险分层更精细。本文综述了MI后HF发生的各种风险预测因素。